Research programme: cancer therapeutics - Tarveda TherapeuticsAlternative Names: Pentarins™
Latest Information Update: 15 Dec 2016
At a glance
- Originator Blend Therapeutics
- Developer Tarveda Therapeutics
- Class Antineoplastons
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Somatostatin receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuroendocrine tumours; Small cell lung cancer; Solid tumours